Your browser is no longer supported. Please, upgrade your browser.
Settings
LBPH [NASD]
Longboard Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.85 Insider Own32.60% Shs Outstand16.86M Perf Week-2.32%
Market Cap156.46M Forward P/E- EPS next Y-2.51 Insider Trans0.00% Shs Float- Perf Month-39.11%
Income-14.40M PEG- EPS next Q-0.94 Inst Own57.60% Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans371.34% Short Ratio0.03 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh3.28 P/C2.83 EPS next 5Y- ROE- 52W Range8.12 - 18.95 Perf YTD-44.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.03% Beta-
Dividend %- Quick Ratio17.70 Sales past 5Y- Gross Margin- 52W Low14.29% ATR1.00
Employees6 Current Ratio17.70 Sales Q/Q- Oper. Margin- RSI (14)29.65 Volatility8.97% 9.94%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.03 Prev Close9.27
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume88.12K Price9.28
Recom- SMA20-15.63% SMA50-31.41% SMA200-31.41% Volume2,230 Change0.11%
Apr-07-21Initiated Evercore ISI Outperform $35
Apr-06-21Initiated Guggenheim Buy $27
Apr-06-21Initiated Citigroup Buy $37
Apr-06-21Initiated Cantor Fitzgerald Overweight $32
Mar-11-21 09:44PM  
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.